文献速递肿瘤 PET/CT核素与放射性配体治疗

转移性去势抵抗性前列腺癌患者接受177Lu-PSMA放射性核素治疗后的早期前列腺特异性抗原变化与临床结局

Early Prostate-Specific Antigen Changes and Clinical Outcome After 177Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · J Nucl Med · 2020-02-28

本回顾性单中心分析纳入124例接受177Lu-PSMA治疗的转移性去势抵抗性前列腺癌患者,按6周时PSA变化分为应答(下降≥30%)、进展(升高≥25%)和稳定三组。6周PSA下降≥30%者总生存期长于稳定组和进展组,且影像学进展风险低于稳定组;6周PSA进展者影像学进展风险高于稳定组,且94%在12周时出现生化进展。作者结论认为6周PSA变化是长期临床结局的早期指标,PSA进展者或可从极早期换药决策中获益,需前瞻性研究验证。

要点

  • 6周PSA下降≥30%者中位总生存16.7个月,长于稳定组11.8个月和进展组6.5个月。
  • 6周PSA下降≥30%者影像学进展风险低于稳定组(HR 0.60),进展者高于稳定组(HR 3.18)。
  • 31例6周PSA进展者中29例(94%)在12周时出现生化进展,仅1例(3%)在12周出现PSA下降。

核心结论

  • 177Lu-PSMA启动后6周PSA变化是长期临床结局的早期指标。
  • 6周治疗PSA进展的患者或可从极早期换药决策中获益。
  • 177Lu-PSMA治疗期间PSA闪烁现象非常少见。
  • 作者认为目前需要前瞻性研究验证上述发现,并可能更早告知临床医生177Lu-PSMA的疗效。

研究设计与样本

  • 回顾性分析,纳入本机构同情用药计划下接受177Lu-PSMA治疗且在基线及治疗启动后6周有PSA值的男性患者。
  • 共124例符合条件的患者具有6周PSA值。
  • 按PSA变化分为3组:应答(下降≥30%)、进展(升高≥25%)、稳定(下降<30%且升高<25%)。
  • 共同主要终点为总生存和影像学无进展生存,次要终点为12周PSA变化和PSA闪烁现象。

主要发现

  • 6周PSA下降≥30%组中位总生存16.7个月(95%CI 14.4-19.0),长于稳定组11.8个月(95%CI 8.6-15.1)(P=0.007)和进展组6.5个月(95%CI 5.2-7.8)(P<0.001)。
  • 6周PSA下降≥30%组影像学进展风险低于稳定组(HR 0.60;95%CI 0.38-0.94;P=0.02)。
  • 6周PSA进展组影像学进展风险高于稳定组(HR 3.18;95%CI 1.95-5.21;P<0.001)。
  • 6周与12周PSA百分比变化高度相关(r=0.90;P<0.001)。
  • 31例6周PSA进展患者中29例(94%)在12周出现生化进展;36例6周PSA进展患者中仅1例(3%)在12周出现任何PSA下降(占整个队列1%)。

关键数值与推荐

  • PSA应答定义为较基线下降≥30%,PSA进展定义为较基线升高≥25%,稳定定义为下降<30%且升高<25%。
  • 6周PSA下降≥30%组中位总生存16.7个月(95%CI 14.4-19.0)。
  • 6周PSA稳定组中位总生存11.8个月(95%CI 8.6-15.1)。
  • 6周PSA进展组中位总生存6.5个月(95%CI 5.2-7.8)。
  • 6周PSA下降≥30%组对比稳定组的影像学进展HR为0.60(95%CI 0.38-0.94;P=0.02);6周PSA进展组对比稳定组的HR为3.18(95%CI 1.95-5.21;P<0.001)。

临床怎么用

  • 作者结论认为177Lu-PSMA启动后6周PSA变化是长期临床结局的早期指标。
  • 作者认为6周治疗PSA进展的患者或可从极早期换药决策中获益。
  • 作者指出177Lu-PSMA治疗期间PSA闪烁现象非常少见。
  • 作者认为目前需要前瞻性研究验证上述发现,并可能更早告知临床医生177Lu-PSMA的疗效。

局限性

  • 研究局限包括其回顾性性质。
  • 研究局限包括单中心经验。
  • 作者认为目前需要前瞻性研究验证上述发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate-specific antigen (PSA) is widely used to monitor treatment response in patients with metastatic castration-resistant prostate cancer. However, PSA measurements are considered only after 12 wk of treatment. We aimed to evaluate the prognostic value of early PSA changes after 177Lu-labeled prostate-specific membrane antigen (177Lu-PSMA) radionuclide treatment in metastatic castration-resistant prostate cancer patients. Methods: Men who were treated with 177Lu-PSMA under a compassionate-access program at our institution and had available PSA values at baseline and at 6 wk after treatment initiation were included in this retrospective analysis. Patients were assigned to 3 groups on the basis of PSA changes: response (≥30% decline), progression (≥25% increase), and stable (<30% decline and <25% increase). The coprimary endpoints were overall survival and imaging-based progression-free survival. The secondary endpoints were PSA changes at 12 wk and PSA flare-up. Results: We identified 124 eligible patients with PSA values at 6 wk. A greater than or equal to 30% decline in PSA at 6 wk was associated with longer overall survival (median, 16.7 mo; 95% CI, 14.4-19.0) than stable PSA (median, 11.8 mo; 95% CI, 8.6-15.1) (P = 0.007) or PSA progression (median, 6.5 mo; 95% CI, 5.2-7.8) (P < 0.001). Patients with a greater than or equal to 30% decline in PSA at 6 wk also had a lower risk of imaging-based progression than patients with stable PSA (hazard ratio, 0.60; 95% CI, 0.38-0.94) (P = 0.02), whereas patients with PSA progression had a higher risk of imaging-based progression than patients with stable PSA (hazard ratio, 3.18; 95% CI, 1.95-5.21) (P < 0.001). The percentage changes in PSA at 6 and 12 wk were highly associated (r = 0.90; P < 0.001). Of 31 patients who experienced early PSA progression at 6 wk, 29 (94%) showed biochemical progression at 12 wk. Overall, only 1 (3%) of 36 patients with PSA progression at 6 wk achieved any PSA decline at 12 wk (1% of the entire cohort). The limitations of the study included its retrospective nature and the single-center experience. Conclusion: PSA changes at 6 wk after 177Lu-PSMA initiation are an early indicator of long-term clinical outcome. Patients with PSA progression after 6 wk of treatment could benefit from a very early decision to switch treatment. PSA flare-up during 177Lu-PSMA treatment is very uncommon. Prospective studies are now warranted to validate our findings and potentially inform clinicians earlier on the effectiveness of 177Lu-PSMA.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Gafita A, Heck MM, Rauscher I, et al. Early Prostate-Specific Antigen Changes and Clinical Outcome After 177Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2020. PMID: 32111687. doi:10.2967/jnumed.119.240242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。